SCHEMBL4773465

SCHEMBL4773465

Oc1cc(-c2cccnc2)nc(-c2ccccn2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.63
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
TP53 P04637 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
PKM P14618 1/20 0.56
TSHR P16473 1/20 0.56
CYP19A1 P11511 4/20 0.51
KDM4E B2RXH2 3/20 0.49
TDP1 Q9NUW8 2/20 0.49
GRM5 P41594 2/20 0.47
PIM1 P11309 1/20 0.47
PIM2 Q9P1W9 1/20 0.47
F2 P00734 1/20 0.46
F12 P00748 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.44
KMO O15229 1/20 0.44
SCN5A Q14524 1/20 0.43
SCN9A Q15858 1/20 0.43
ABL1 P00519 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24589930 0.85 CYP2A6 (0.67) CYP2A6NPC1RAB9ATP53SMN1; SMN2
SCHEMBL10168729 0.84 CYP19A1 (0.62) CYP2A6NPC1RAB9ATP53SMN1; SMN2
SCHEMBL4773440 0.82 CYP2A6 (0.63) CYP2A6NPC1RAB9ATP53SMN1; SMN2
SCHEMBL2239691 0.82 CYP2A6 (0.63) CYP2A6NPC1RAB9ATP53SMN1; SMN2
SCHEMBL19047219 0.82 CYP2A6 (0.63) CYP2A6NPC1RAB9ATP53SMN1; SMN2
SCHEMBL16606290 0.81 CYP2A6 (0.70) CYP2A6NPC1RAB9ATP53SMN1; SMN2
SCHEMBL4340551 0.81 KDM4E (0.63) NPC1RAB9ATP53SMN1; SMN2PKM
SCHEMBL1443106 0.81 KDM4E (0.68) NPC1RAB9ATP53SMN1; SMN2PKM
SCHEMBL19037577 0.79 CYP2A6 (0.58) CYP2A6NPC1RAB9ATP53SMN1; SMN2
[2,3'']Bipyridinyl SCHEMBL29360744 0.79 CYP2A6 (1.00) CYP2A6NPC1RAB9ATP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed